Amber TX
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
242 Acklam Rd, London, Greater London, W...Website
www.amber-tx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Amber TX
Amber Therapeutics is pioneering an adaptive neuromodulation therapy specifically designed for women suffering from mixed urinary incontinence. Their flagship product, the Picostim System, is a fully implantable device that interacts with the pudendal nerve, dynamically adjusting to individual physiological responses. The company aims to address a pressing global health issue, providing effective treatment options for the estimated 40 million women in the US who experience this condition, with only a fraction receiving appropriate care. Founded in 2021, Amber Therapeutics combines a multi-disciplinary team with deep expertise in medical devices to transform lives through innovation.Explore more
Amber TX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amber TX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Amber TX is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Amber TX
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Amber TX had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Amber TX has new funding data
Product Launch: Get notified when Amber TX launches new products
Amber TX, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Amber TX recently announced quarterly report
Check if Amber TX has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Amber TX
Find 3 more new buyers
Compare Similar Companies to Amber TX
Compare insights from companies similar to Amber TX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Amber TX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amber TX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amber TX.
Amber TX financials insights
Gather financial insights about Amber TX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$100M
Amber TX Tech Stack
A closer look at the technologies used by Amber TX
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Funding
Funding
Mergers & Acquisitions (M&A)
Amber TX News & Media
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
London, UK. 10th June 2024 - Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence (MUI), announces the successful closing of its Series A financing raising a total of $100 million (£80 million) from leading healthcare and technology investors in the US and UK.Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
London, UK, 27 February 2024 – Amber Therapeutics (‘Amber’ or the ‘Company’), an innovative medical technology company developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces the presentation of the first data from its AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study evaluating Amber-UI.Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developed
London and Bristol, UK. 5 September 2023 - Amber Therapeutics (‘Amber’ or the ‘Company’) announces it has acquired Bioinduction Limited (‘Bioinduction’) and its Picostim DyNeuMo neuromodulation therapy platform. Amber is using the platform to explore a closed-loop therapy for mixed urinary incontinence (Amber-UI). The acquisition supports the Company’s strategy to develop intelligent, transformative neuromodulation therapies for patients with functional disorders of the nervous system. Financial
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amber TX
Sign Up For FreeTo access detailed company insights
Amber Therapeutics is pioneering an adaptive neuromodulation therapy specifically designed for women suffering from mixed urinary incontinence. Their flagship product, the Picostim System, is a fully implantable device that interacts with the pudendal nerve, dynamically adjusting to individual physiological responses. The company aims to address a... Read More
